Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin

Journal of International Medical Research

Volumn 36, Issue 6, 2008, Pages 1273-1278

  Dong, M ^a   Li, X ^a   Hong, Luo Jia ^a   Xie, R ^a   Zhao, H L ^a   Li, K ^a   Wang, H H ^a   Shin, W D ^a   Shen, H J ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Gene therapy; Malignant peritoneal effusion; Malignant pleural effusion; Recombinant adenovirus p53

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; FUROSEMIDE; METHYLPREDNISOLONE; PROTEIN P53; TUMOR MARKER; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MALIGNANT NEOPLASTIC DISEASE; PLEURA EFFUSION; PROTEIN BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ASCITES FLUID; BLOOD; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN ADENOVIRUS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADENOVIRUSES, HUMAN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASCITES; ASCITIC FLUID; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; GENES, P53; HUMANS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59649095034     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600614     Document Type: Article

References (22)

1. Monti P, Ciribilli Y, Jordan J, et al: Transcriptional functionality of germ line p53 mutants influences cancer phenotype. Clin Cancer Res 2007; 13: 3789-3795.
2. Ostrowski MJ: An assessment of the long-term results of controlling the reaccumulation of malignant effusion using intracavity bleomycin. Cancer 1986: 57: 721-727.
3. Zhou JC: Practice of Medical Oncology 2nd edn. Beijing: People's Medical Publishing House, vol 5, 2005; pp 47-48 [in Chinese].
4. Guo Y, Zen Y, Wang K, et al: Therapeutic potential of recombinant adenovirus expressing p53 in hepatocellular carcinoma cell lines. Chin J Hepatol 2001; 9: 43-45 [in Chinese].
5. Swisher SG, Roth JA: Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am 2002; 11: 521-535.
6. Guo Y, Wang C, Chen JS, et al: Therapeutic potential of recombinant adenovirus expressing p53 on hepatocellular carcinoma cells possessing different p53 functional status. Chin J Gen Surg 2001; 16: 722-724 [in Chinese].
7. Quist SR, Wang-Grohrke S, Köhler T, et al: Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther 2004; 11: 547-554.
8. Peng Z: Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027.
9. Wang JH, Ji ZZ, Yan LK, et al: The expression of p53 in posttransfection cells with rAd-p53 gene and inhibition activity in vitro. Cancer Res Prevention Treatment 2007; 34: 185-188 [in Chinese].
10. Swisher SG, Roth JA, Komaki R, et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9: 93-101.
11. Buller RE, Runnebaum IB, Karlan BY, et al: A phase L/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566.
12. Qi X-D, Yang Z-B, Han D-M, et al: The clinical effect of recombinant human Ad. p53 agent-Gendicine in advance cancer patients. Modern Oncol 2006; 14: 1295-1297 [in Chinese].
13. Zhang S-W, Xiao S-W, Liu C-Q: Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases. National Medical Journal of China 2003; 23: 2033-2035.
14. Zhou JC: Practice of Medical Oncology, 2nd edn. Beijing: People's Medical Publishing House, vol 5, 2005; pp 92-95 [in Chinese].
15. Yuan P, Miao XP Zhang XM, et al: Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms. Zhonghua Zhong Lu Za Zhi 2006; 28: 107-110 [in Chinese, English abstract].
16. Jagelská EB, Brázda V, Pecinka P, et al: DNA topology influences p53 sequence-specific DNA binding through structural transitions within the target sites. Biochem J 2008; 412: 57-63.
17. Di Ventura B, Funaya C, Antony C, et al: Reconstitution of Mdm2-dependent posttranslational modifications of p53 in yeast. PloS ONE 2008; 3: e1507.
18. Ohta M, Tateishi K, Kanai F, et al: p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res 2005; 65: 10822-10829.
19. Tian Y, Ding RY, Zhi YH, et al: Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 2006; 12: 415-419.
20. Gai XD, Li Gl, Huanh JZ, et al: Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms. Ai Zheng 2006; 25: 954-959 [in Chinese, English abstract].
21. Hostel LJ, Hussain SP, Harris CC: p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25: 177-181.
22. Zumstein LA, Call C, Merritt J, et al: Safety of adenoviral vectors: results of clinical investigations of 445 cancer patients treated with Advexin® (adenoviral p53) gene therapy. Mol Ther 2004; 9(suppl 1): S385-S386.